Urelumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Urelumab
Accession Number
DB12077
Description

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • BMS 663513
  • BMS-663513
  • BMS-66513

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 9Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Urelumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Urelumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Urelumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Urelumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Urelumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Urelumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Urelumab.
AvelumabThe risk or severity of adverse effects can be increased when Avelumab is combined with Urelumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
230902QLLC
CAS number
934823-49-1

References

General References
Not Available
PubChem Substance
347911279
Wikipedia
Urelumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMelanoma1
2RecruitingTreatmentCancer, Bladder / Transitional Cell Carcinoma1
2WithdrawnTreatmentLeukemias1
1Active Not RecruitingTreatmentGlioblastomas / Gliosarcoma / Recurrent Brain Neoplasm1
1Active Not RecruitingTreatmentMalignancies1
1CompletedTreatmentB-Cell Malignancies1
1CompletedTreatmentCancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma1
1CompletedTreatmentColorectal Cancers / Head and Neck Carcinoma1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasms Malignant1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
Gene Name
TNFRSF9
Uniprot ID
Q07011
Uniprot Name
Tumor necrosis factor receptor superfamily member 9
Molecular Weight
27898.6 Da

Drug created on October 20, 2016 15:18 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates